SCIENTIFIC PROGRAM


IMMUNOTHERAPY BRIDGE
December 2nd-3rd, 2020
VIRTUAL MEETING




The program schedule has been defined to allow speakers to connect for live sessions considering the different time zones.


December 2
nd 2020
01.00 PM Introduction and objectives, Paolo A. Ascierto


SITC Session - BIOMARKERS
Chairpersons: Paolo A. Ascierto, Bernard Fox, Patrick Hwu

01.10 PM Multiplex Immunofluorescence assay development: current status and future directions, Janis M. Taube
01.25 PM Integrating multiomics in the practice of diagnostic pathology, Carlo Bifulco
01.40 PM Leveraging other genomes as potential response biomarkers: the microbiome, Jennifer McQuade
01.55 PM Biomarkers Task Force, Chrystal Paulos
02.10 PM Chewing through the fat: metabolic regulation of anti-tumor immunity, Susan M. Kaech
02.25 PM Best of SITC for clinical development and trials, Paolo A. Ascierto
02.40 PM Discussion on biomarkers, Paolo A. Ascierto, Bernard Fox, Patrick Hwu
03.10 PM Break**

SESSION 2 TRENDS IN IMMUNOTHERAPY
Chairpersons: Paolo A. Ascierto, Daniele Bruno, John Haanen

03.25 PM Kidney Cancer, Camillo Porta
03.55 PM SYMPOSIUM Combined Therapy
The role of combined therapies across tumor types
Paolo A. Ascierto, Cesare Gridelli, Sara Lonardi
04.45 PM Break**
05.00 PM The role of combined chemo-immunotherapy in first-line treatment of advanced NSCLC, Cesare Gridelli
05.15 PM Breast cancer immunotherapy: biomarkers and clinical benefit, Leisha Emens
05.30 PM Immunotherapy for HPV related Head&Neck cancer, Robert Ferris
05.45 PM Therapeutic strategies to sensitize prostate cancer to immunotherapy: from bedside to bench and back, Akash Patnaik
06.00 PM Break**
06.15 PM Adaptive metabolic rewiring of the tumor microenvironment impedes efficacy of IDO blockade in ovarian cancer, kunle Odunsi
06.30 PM Immunotherapy in GI Cancer, Fortunato Ciardiello
06.45 PM Merkel Cell carcinoma, Paolo A. Ascierto
07.00 PM Discussion on trends in immunotherapy, Paolo A. Ascierto, Daniele Bruno, John Haanen






December 3rd 2020

SESSION 3 DRIVERS OF IMMUNE RESPONSES
Chairpersons: Paolo A. Ascierto, Alfredo Budillon, Luigi Buonaguro

01.00 PM Mechanisms of immunotherapy response and resistance, Jerome Galon
01.15 PM Breast cancer, radiation and immunotherapy, Silvia Formenti
01.30 PM Lymphomas, John Timmerman
01.45 PM Revolt of the T cell system against anti-PD1 immunotherapy, Samir N. Khleif
02.00 PM Break**
02.15 PM Transcriptional imprints of inherited T-cell regulome modulating immunotherapy outcomes, Tomas Kirchhoff
02.30 PM T cell differentiation states in the irradiated tumor microenvironment that drive responses to CTLA-4 blockade, Sandra Demaria
02.45 PM Discussion on drivers of immune responses, Paolo A. Ascierto, Alfredo Budillon, Luigi Buonaguro
03.15 PM SYMPOSIUM Non-Melanoma Skin Cancer
Non-melanoma skin cancer updates of new developments at ASCO and ESMO 2020
Dirk Schadendorf, Paolo A. Ascierto
04.05 PM Break**


GREAT DEBATE SESSION
Chairpersons: Paolo A. Ascierto, Bernard Fox, Patrick Hwu, Igor Puzanov

04.20 PM Antitumoral vaccination is still an option: yes or not? Lisa H. Butterfield, Olivera J. Finn
04.45 PM Discussion on "Antitumoral vaccination is still an option: yes or not?" Paolo A. Ascierto, Bernard Fox, Patrick Hwu, Igor Puzanov
04.55 PM Is anti PD-1 / PDL1 a backbone for immunotherapy combination: yes or not? Ryan J. Sullivan, Joshua Brody
05.25 PM Discussion on "Is anti PD-1 / PDL1 a backbone for immunotherapy combination: yes or not?" Paolo A. Ascierto, Bernard Fox, Patrick Hwu, Igor Puzanov
05.35 PM Break**
05.50 PM Do we need an innovative studies design and is overall survival the endpoint? Point of view of Academia, "regulators", Company Francesco Perrone, Marc Theoret, John Goldberg
06.35 PM Discussion on "Do we need an innovative studies design and is overall survival the endpoint?" Paolo A. Ascierto, Bernard Fox, Patrick Hwu, Igor Puzanov
06.45 PM What we will do on Monday? Sanjiv S. Agarwala
07.00 PM Break**


SESSION NEOADJUVANT IMMUNOTHERAPY ACROSS CANCERS
Chairpersons: Paolo A. Ascierto, Elizabeth M. Burton

07.15 PM From the clinic to the lab: investigating mechanisms of response and resistance to immune checkpoint therapy, Padmanee Sharma
07.30 PM Neoadjuvant immunotherapy in Breast Cancer ,Leisha Emens
07.45 PM Neoadjuvant immunotherapy for operable non-small cell lung cancer: lessons learned and current challenges, Tina Cascone
08.00 PM Neoadjuvant therapy in melanoma, Rodabe N. Amaria
08.15 PM Towards a Pan-tumor scoring system of pathologic response to immunotherapy, Janis M. Taube
08.30 PM Discussion on Neo Adjuvant immunotherapy across cancers, Paolo A. Ascierto, Elizabeth M. Burton
09.00 PM Conclusions, Paolo A. Ascierto, Bernard Fox, Patrick Hwu, Igor Puzanov


** Not included in the CME accredited program

For information please contact info@melanomabridge.org